14.78

4.16% +0.59

After Hours: 14.51 -0.27 -1.83%

NovoCure Ltd (NVCR)

Overview News Price History Option Chain Financials Why NVCR Down? Discussions Forecast

NovoCure Ltd stock is currently priced at $14.78, with a 24-hour trading volume of 1.14M. It has seen a +4.16% increased in the last 24 hours and a +2.50% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $13.52 pivot point. If it approaches the $14.88 resistance level, significant changes may occur.

Previous Close:

$14.19

Open:

$14.65

24h Volume:

1.14M

Market Cap:

$1.56B

Revenue:

$509.34M

Net Income/Loss:

$-207.04M

P/E Ratio:

-7.9462

EPS:

-1.86

Net Cash Flow:

$-100.43M

1W Performance:

+16.98%

1M Performance:

+2.50%

6M Performance:

+7.26%

1Y Performance:

-77.59%

1D Range:

$14.31

$15.42

52W Range:

$10.87

$83.60

NovoCure Ltd Stock (NVCR) Company Profile

Name

NovoCure Ltd

Sector

Healthcare (1221)

Industry

Medical Devices (156)

Phone

Address

Employee

495

Twitter

@novocure

Next Earnings Date

2024-05-02

Latest SEC Filings

NVCR's Discussions on Twitter

NovoCure Ltd Stock (NVCR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-28-23	Downgrade	H.C. Wainwright	Buy → Neutral
Aug-08-23	Upgrade	Piper Sandler	Neutral → Overweight
Aug-04-23	Initiated	SVB Securities	Outperform
Jul-31-23	Upgrade	Evercore ISI	Underperform → In-line
Jun-07-23	Upgrade	Wedbush	Underperform → Neutral
May-16-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Mar-17-23	Downgrade	JP Morgan	Neutral → Underweight
Jan-06-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Jan-05-23	Reiterated	H.C. Wainwright	Buy
Nov-29-22	Upgrade	Wells Fargo	Equal Weight → Overweight
Oct-24-22	Downgrade	Piper Sandler	Overweight → Neutral
Jul-05-22	Downgrade	Evercore ISI	In-line → Underperform
May-16-22	Initiated	H.C. Wainwright	Buy
Feb-08-22	Initiated	Loop Capital	Buy
Feb-02-22	Upgrade	Oppenheimer	Perform → Outperform
Jan-20-22	Upgrade	Truist	Hold → Buy
Jan-03-22	Upgrade	Evercore ISI	Underperform → In-line
Jul-01-21	Downgrade	Mizuho	Buy → Neutral
Apr-14-21	Downgrade	Wedbush	Neutral → Underperform
Jan-25-21	Reiterated	Piper Sandler	Overweight
Sep-23-20	Initiated	Northland Capital	Outperform
Sep-18-20	Downgrade	Wells Fargo	Overweight → Equal Weight
Sep-17-20	Downgrade	Truist	Buy → Hold
Jun-01-20	Resumed	Oppenheimer	Perform
May-01-20	Downgrade	Oppenheimer	Outperform → Perform
Apr-09-20	Downgrade	Evercore ISI	In-line → Underperform
Mar-05-20	Upgrade	Wells Fargo	Equal Weight → Overweight
Jan-02-20	Downgrade	Evercore ISI	Outperform → In-line
Jul-29-19	Upgrade	SunTrust	Hold → Buy
Jul-26-19	Downgrade	JP Morgan	Overweight → Neutral
Jul-26-19	Downgrade	Wedbush	Outperform → Neutral
Mar-20-19	Initiated	SunTrust	Hold
Nov-02-18	Downgrade	Wells Fargo	Outperform → Market Perform
Jul-16-18	Initiated	Evercore ISI	Outperform
Apr-18-18	Reiterated	Mizuho	Buy
Feb-23-18	Reiterated	Mizuho	Buy
May-24-17	Upgrade	Wells Fargo	Market Perform → Outperform
Jul-29-16	Reiterated	Wedbush	Outperform
Jan-19-16	Initiated	Barclays	Underweight
Dec-02-15	Initiated	Deutsche Bank	Hold